Bart Wuurman, Chief Executive Officer
As multiple entrepreneur and pharmaceutical scientist, Bart Wuurman has been instrumental to the success of everal biotech companies, including Lanthio Pharma and AM-Pharma in The Netherlands and Antisoma in the United Kingdom. He was involved with raising approximately € 80 million in equity funding. Before becoming CEO, Bart was VP Business Development and Licensing for Antisoma plc and Medeva plc in the United Kingdom, where he was responsible for out-licensing deals worth over €700 million.
Bart Wuurman, Chief Executive OfficerAs multiple entrepreneur and pharmaceutical scientist, Bart Wuurman has been instrumental to the success of everal biotech companies, including Lanthio Pharma and AM-Pharma in The Netherlands and Antisoma in the United Kingdom. He was involved with raising approximately € 80 million in equity funding. Before becoming CEO, Bart was VP Business Development and Licensing for Antisoma plc and Medeva plc in the United Kingdom, where he was responsible for out-licensing deals worth over €700 million.
Prof. Dr. David Sherr, Chief Scientific OfficerProf Dr David Sherr is a founder of Hercules and has published over 100 peer-reviewed articles, many of which relate to AhR in cancer. David is Director of the Immunology Training Program at Boston University School Of Medicine and Director of the Boston University Superfund Research Program.